5bzd: Difference between revisions

← Older edit

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA

@@ Line 1: / Line 1: @@
 ==Crystal Structure of PCDN-27A, an antibody from the PCDN family of HIV-1 antibodies==
-<StructureSection load='5bzd' size='340' side='right' caption='[[5bzd]], [[Resolution|resolution]] 2.70&Aring;' scene=''>
+<StructureSection load='5bzd' size='340' side='right'caption='[[5bzd]], [[Resolution|resolution]] 2.70&Aring;' scene=''>
 == Structural highlights ==
-<table><tr><td colspan='2'>[[5bzd]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5BZD OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5BZD FirstGlance]. <br>
+<table><tr><td colspan='2'>[[5bzd]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5BZD OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=5BZD FirstGlance]. <br>
-</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
+</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.7&#8491;</td></tr>
-<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5bzw|5bzw]]</td></tr>
+<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene></td></tr>
-<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5bzd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5bzd OCA], [http://pdbe.org/5bzd PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5bzd RCSB], [http://www.ebi.ac.uk/pdbsum/5bzd PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5bzd ProSAT]</span></td></tr>
+<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=5bzd FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5bzd OCA], [https://pdbe.org/5bzd PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=5bzd RCSB], [https://www.ebi.ac.uk/pdbsum/5bzd PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=5bzd ProSAT]</span></td></tr>
 </table>
+<div style="background-color:#fffaf0;">
+== Publication Abstract from PubMed ==
+The high-mannose patch on HIV Env is a preferred target for broadly neutralizing antibodies (bnAbs), but to date, no vaccination regimen has elicited bnAbs against this region. Here, we present the development of a bnAb lineage targeting the high-mannose patch in an HIV-1 subtype-C-infected donor from sub-Saharan Africa. The Abs first acquired autologous neutralization, then gradually matured to achieve breadth. One Ab neutralized &gt;47% of HIV-1 strains with only approximately 11% somatic hypermutation and no insertions or deletions. By sequencing autologous env, we determined key residues that triggered the lineage and participated in Ab-Env coevolution. Next-generation sequencing of the Ab repertoire showed an early expansive diversification of the lineage followed by independent maturation of individual limbs, several of them developing notable breadth and potency. Overall, the findings are encouraging from a vaccine standpoint and suggest immunization strategies mimicking the evolution of the entire high-mannose patch and promoting maturation of multiple diverse Ab pathways.
+Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.,MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, Ramos A, Bian CB, Wickramasinghe L, Kong L, Eren K, Wu CY, Wong CH, Kosakovsky Pond SL, Wilson IA, Burton DR, Poignard P Immunity. 2016 May 17;44(5):1215-26. doi: 10.1016/j.immuni.2016.04.016. PMID:27192579<ref>PMID:27192579</ref>
+From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+</div>
+<div class="pdbe-citations 5bzd" style="background-color:#fffaf0;"></div>
+==See Also==
+*[[Antibody 3D structures|Antibody 3D structures]]
+*[[Sandbox 20009|Sandbox 20009]]
+*[[3D structures of human antibody|3D structures of human antibody]]
+== References ==
+<references/>
 __TOC__
 </StructureSection>
-[[Category: Garces, F]]
+[[Category: Homo sapiens]]
-[[Category: WILSON, I A]]
+[[Category: Large Structures]]
-[[Category: Antibody]]
+[[Category: Garces F]]
-[[Category: Fab]]
+[[Category: WILSON IA]]
-[[Category: Hiv]]
-[[Category: Immune system]]